

CITATION REPORT

List of articles citing

Huntington disease: natural history, biomarkers and prospects for therapeutics

DOI: 10.1038/nrneurol.2014.24

Nature Reviews Neurology, 2014, 10, 204-16.

Source: <https://exaly.com/paper-pdf/58820590/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
713	Neurochemical dissociation of memory systems. 1987 , 37, 789-94		286
712	Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. 2014 , 6, 78		145
711	Rectifying rectifier channels in Huntington disease. 2014 , 7, e29410		2
710	Chorea associated with Huntington's disease: to treat or not to treat?. 2014 , 29, 1414-8		39
709	Huntington's disease: a field on the move. Introduction. 2014 , 29, 1333-4		3
708	Chapter 22:Manganese and Huntington Disease. 2014 , 540-573		2
707	Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction. 2014 , 29, 1351-8		63
706	Regenerative medicine in Huntington's disease: current status on fetal grafts and prospects for the use of pluripotent stem cell. 2014 , 170, 749-62		15
705	Diagnostic criteria for Huntington's disease based on natural history. 2014 , 29, 1335-41		110
704	An update on Huntington's disease: from the gene to the clinic. 2014 , 27, 477-83		28
703	Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies. 2014 , 5, 132		43
702	Astrocytes go awry in Huntington's disease. 2014 , 17, 641-2		9
701	Targets for future clinical trials in Huntington's disease: what's in the pipeline?. 2014 , 29, 1434-45		104
700	Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. 2014 , 13, 1193-201		159
699	What is the course of Huntington's disease?. 2014 , 13, 1165-6		3
698	Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. 2014 , 29, 1419-28		35
697	The neurology of mTOR. 2014 , 84, 275-91		418

696	Potential therapeutic targets in polyglutamine-mediated diseases. 2014 , 14, 1215-28	14
695	Brûe: Huntington, prÛent et futur. 2014 , 25, 9	
694	Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease. 2014 , 29, 1429-33	21
693	The role of microglia in human disease: therapeutic tool or target?. 2014 , 128, 363-80	89
692	Human-induced pluripotent stem cells: potential for neurodegenerative diseases. 2014 , 23, R17-26	87
691	The rise of large-scale imaging studies in psychiatry. 2014 , 3, 29	18
690	Sirtuin 1 activator SRT2104 protects Huntington's disease mice. 2014 , 1, 1047-52	33
689	Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD. 2015 , 30, 1664-72	30
688	Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets. 2015 , 3, e00104	3
687	Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease. 2015 , 29, 949-60	10
686	Huntingtin Exists as Multiple Splice Forms in Human Brain. 2015 , 4, 161-71	8
685	Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. 2015 , 7, 1547-64	62
684	Nuclear retention of full-length HTT RNA is mediated by splicing factors MBNL1 and U2AF65. 2015 , 5, 12521	34
683	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. 2015 , 2, 1420-9	91
682	The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model. 2015 , 10, 67	32
681	T1Ûmaging in premanifest Huntington disease reveals changes associated with disease progression. 2015 , 30, 1107-14	14
680	Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study. 2015 , 41, 843-8	23
679	The role of the immune system in triplet repeat expansion diseases. 2015 , 2015, 873860	22

678	Network Neurodegeneration in Alzheimer's Disease via MRI Based Shape Diffeomorphometry and High-Field Atlasing. 2015 , 3, 54	30
677	Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model. 2015 , 10, e0134142	53
676	HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation. 2015 , 10, e0134465	14
675	A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease. 2015 , 10, e0138848	15
674	Protective Effects of Aqueous Extract of Luehea divaricata against Behavioral and Oxidative Changes Induced by 3-Nitropropionic Acid in Rats. 2015 , 2015, 723431	12
673	PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD). 2015 , 14, 1716-29	40
672	Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases. 2015 , 7, 502-11	26
671	Huntington Disease. 2015 , 199-225	
670	Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. 2015 , 85, 1212-26	89
669	Preserving cortico-striatal function: deep brain stimulation in Huntington's disease. 2015 , 9, 32	14
668	Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. 2015 , 112, 14078-83	36
667	Random Forest Classification of Depression Status Based On Subcortical Brain Morphometry Following Electroconvulsive Therapy. 2015 , 2015, 92-96	8
666	N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice. 2015 , 85, 726-41	48
665	Network topology and functional connectivity disturbances precede the onset of Huntington's disease. 2015 , 138, 2332-46	75
664	Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. 2015 , 162, 516-26	378
663	Guidelines for presymptomatic testing for Huntington's disease: past, present and future in France. 2015 , 171, 572-80	11
662	Circadian regulation of slow waves in human sleep: Topographical aspects. 2015 , 116, 123-34	52
661	GeneEnvironment Interactions in Huntington's Disease. 2015 , 355-383	

660	Selective autophagy and Huntingtin: learning from disease. 2015 , 14, 1617-8	9
659	Functional brain changes underlying irritability in premanifest Huntington's disease. 2015 , 36, 2681-90	25
658	Huntington's disease: looking beyond the movement disorder. 2015 , 34, 135-42	15
657	Huntington disease. 2015 , 1, 15005	672
656	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. 2015 , 125, 1979-86	144
655	Genetic testing and counseling in the diagnosis and management of young-onset dementias. 2015 , 38, 295-308	26
654	Dopamine and Huntington's disease. 2015 , 15, 445-58	43
653	Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. 2015 , 23, 1759-1771	54
652	Treating the whole body in Huntington's disease. 2015 , 14, 1135-42	96
651	Developing stem cell therapies for juvenile and adult-onset Huntington's disease. 2015 , 10, 623-46	29
650	Use of a force-sensing automated open field apparatus in a longitudinal study of multiple behavioral deficits in CAG140 Huntington's disease model mice. 2015 , 294, 7-16	11
649	Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice. 2015 , 311, 519-38	30
648	In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases. 2015 , 73, 3-12	7
647	Neuropsychiatric Symptoms of Movement Disorders. 2015 ,	
646	Disease-Associated Changes in the Striosome and Matrix Compartments of the Dorsal Striatum. 2016 , 24, 783-802	6
645	Abnormal eye movements in three types of chorea. 2016 , 74, 761-766	4
644	Revisiting the neuropsychiatry of Huntington's disease. 2016 , 10, 261-266	14
643	Juvenile Huntington disease in Argentina. 2016 , 74, 50-4	8

642	Novel targets for Huntington's disease: future prospects. 2016 , 6, 25-36	6
641	Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. 2016 , 8, 1485-512	138
640	Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease. 2016 , 39, 379-91	22
639	Bile Acids in Neurodegenerative Disorders. 2016 , 8, 263	59
638	Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review. 2016 , 9, 27	33
637	Neurodegenerative Diseases: Might Citrus Flavonoids Play a Protective Role?. 2016 , 21,	77
636	Protein-Nanoparticle Interaction-Induced Changes in Protein Structure and Aggregation. 2016 , 11, 1869-77	35
635	Psychiatric and cognitive symptoms in Huntington's disease are modified by polymorphisms in catecholamine regulating enzyme genes. 2016 , 89, 320-7	10
634	Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. 2016 , 25, 677-86	32
633	Clinical Exercise Science. 2016 ,	
632	Comparative analysis of anti-polyglutamine Fab crystals grown on Earth and in microgravity. 2016 , 72, 762-771	3
631	Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity. 2016 , 6, 31022	20
630	Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington's disease. 2016 , 6, 28322	15
629	Cerebrospinal Fluid Biomarkers for Huntington's Disease. 2016 , 5, 1-13	39
628	The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. 2016 , 282, 99-118	33
627	Linking white matter and deep gray matter alterations in premanifest Huntington disease. 2016 , 11, 450-460	39
626	Circulating microRNAs in Huntington's disease: Emerging mediators in metabolic impairment. 2016 , 108, 102-110	46
625	Resting-state fMRI reveals potential neural correlates of impaired cognition in Huntington's disease. 2016 , 27, 41-6	16

624	Current status of PET imaging in Huntington's disease. 2016 , 43, 1171-82	58
623	Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington's disease peripheral blood samples. 2016 , 12, 137	29
622	Diffusion imaging studies of Huntington's disease: A meta-analysis. 2016 , 32, 94-101	21
621	Huntington's disease: Molecular basis of pathology and status of current therapeutic approaches. 2016 , 12, 1951-1956	11
620	Magnetic Resonance Spectroscopy in Huntington's Disease. 2016 , 103-120	1
619	Quantitative Proteomic Analysis Reveals Similarities between Huntington's Disease (HD) and Huntington's Disease-Like 2 (HDL2) Human Brains. 2016 , 15, 3266-83	18
618	Modeling Variability in the Progression of Huntington's Disease A Novel Modeling Approach Applied to Structural Imaging Markers from TRACK-HD. 2016 , 5, 437-45	12
617	Clinical and genetic characteristics in patients with Huntington's disease from China. 2016 , 38, 916-20	6
616	Magnetic Resonance Spectroscopy of Degenerative Brain Diseases. 2016 ,	0
615	Subcortical contributions to large-scale network communication. 2016 , 71, 313-322	83
614	HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). 2016 , 25, 2441-2455	34
613	Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease. 2016 , 31, 1664-1675	24
612	Neuroendocrine and neurotrophic signaling in Huntington's disease: Implications for pathogenic mechanisms and treatment strategies. 2016 , 71, 444-454	18
611	Studying the pathophysiologic connection between cardiovascular and nervous systems using stem cells. 2016 , 94, 1499-1510	11
610	Huntington's Disease: The Most Curable Incurable Brain Disorder?. 2016 , 8, 3-4	5
609	Huntington disease reduced penetrance alleles occur at high frequency in the general population. 2016 , 87, 282-8	48
608	Metabolic profiling for the identification of Huntington biomarkers by on-line solid-phase extraction capillary electrophoresis mass spectrometry combined with advanced data analysis tools. 2016 , 37, 795-808	26
607	Impact of Huntington Disease Gene-Positive Status on Pre-Symptomatic Young Adults and Recommendations for Genetic Counselors. 2016 , 25, 1188-1197	16

606	The P42 peptide and Peptide-based therapies for Huntington's disease. 2016 , 11, 24	14
605	Chronic subdural hematomas in Finnish patients with Huntington's disease. 2016 , 158, 1487-90	3
604	Early GABAergic transmission defects in the external globus pallidus and rest/activity rhythm alteration in a mouse model of Huntington's disease. 2016 , 329, 363-79	19
603	Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology. 2016 , 115, 2124-46	15
602	High-speed video gait analysis reveals early and characteristic locomotor phenotypes in mouse models of neurodegenerative movement disorders. 2016 , 311, 340-353	22
601	Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT. 2016 , 52, 66-74	13
600	Behavioral phenotyping of minipigs transgenic for the Huntington gene. 2016 , 265, 34-45	15
599	Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington's disease human brain. 2016 , 1862, 1650-62	27
598	HSF Inhibits the Progression of Age-Related Neurodegenerative Diseases. 2016 , 213-242	
597	Classification of Huntington's disease stage with support vector machines: A study on oculomotor performance. 2016 , 48, 1667-1677	7
596	Heat Shock Factor. 2016 ,	9
595	Disorders of Movement. 2016 ,	8
594	Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns. 2016 , 263, 290-298	21
593	Ethical aspects of a predictive test for Huntington's Disease: A long term perspective. 2016 , 23, 565-75	7
592	Neuroimaging of a minipig model of Huntington's disease: Feasibility of volumetric, diffusion-weighted and spectroscopic assessments. 2016 , 265, 46-55	15
591	Use of human stem cells in Huntington disease modeling and translational research. 2016 , 278, 76-90	25
590	Motor network structure and function are associated with motor performance in Huntington's disease. 2016 , 263, 539-49	20
589	Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. 2016 , 19, 623-33	219

588	Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. 2016 , 113, 3359-64	86
587	Rapid Intermittent Involuntary Movements. 2016 , 305-359	
586	Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease. 2016 , 37, 789-96	67
585	Purinergic neurone-glia signalling in cognitive-related pathologies. 2016 , 104, 62-75	23
584	MAP2 Splicing is Altered in Huntington's Disease. 2017 , 27, 181-189	15
583	White matter predicts functional connectivity in premanifest Huntington's disease. 2017 , 4, 106-118	21
582	Total recognition discriminability in Huntington's and Alzheimer's disease. 2017 , 39, 120-130	3
581	TLR4/MD2 specific peptides stalled in vivo LPS-induced immune exacerbation. 2017 , 126, 49-60	28
580	The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention. 2017 , 32, 96-110	42
579	Putaminal Hypometabolism Exceeding Caudate Abnormalities on 18F-FDG PET in Huntington Disease. 2017 , 42, e343-e344	2
578	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. 2017 , 88, 152-159	75
577	Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington's disease: A cross-validation study in Q175 knock-in mice. 2017 , 98, 66-76	24
576	Validation of a prognostic index for Huntington's disease. 2017 , 32, 256-263	27
575	Computational psychiatry: Advancing predictive modeling of neurodegeneration with neuroimaging of Huntington's disease. 2017 , 61, 4:1-4:10	1
574	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. 2017 , 16, 601-609	172
573	Potential biomarker breakthrough for Huntington's disease. 2017 , 16, 573-574	
572	New developments in RAN translation: insights from multiple diseases. 2017 , 44, 125-134	62
571	The Endocannabinoid System in Local and Systemic Inflammation. 2017 , 9, i-192	1

570	Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels. 2017 , 26, 1258-1267	10
569	Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease. 2017 , 7, 44849	31
568	The Danish HD Registry-a nationwide family registry of HD families in Denmark. 2017 , 92, 338-341	4
567	Developmental Whole Brain White Matter Alterations in Transgenic Huntington's Disease Monkey. 2017 , 7, 379	21
566	Integrated electrokinetically driven microfluidic devices with pH-mediated solid-phase extraction coupled to microchip electrophoresis for preterm birth biomarkers. 2017 , 38, 1743-1754	16
565	Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease. 2017 , 7, 43841	10
564	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. 2017 , 38, 2819-2829	17
563	Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. 2017 , 20, 648-660	124
562	The Confluence of Psychiatric Symptoms and Neurodegenerative Disease: Impact on Genetic Counseling. 2017 , 26, 435-441	5
561	Misdiagnosis of Huntington's disease. 2017 , 4, 21	3
560	Investigational agents for the management of Huntington's disease. 2017 , 26, 175-185	8
559	Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration. 2017 , 38, 1460-1477	31
558	DNA repair: A unifying mechanism in neurodegeneration. 2017 , 541, 34-35	35
557	Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. 2017 , 6, 189-199	10
556	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. 2017 , 7, 14275	11
555	Genome engineering: a new approach to gene therapy for neuromuscular disorders. <i>Nature Reviews Neurology</i> , 2017 , 13, 647-661	15 45
554	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. 2017 , 74, 1352-1360	10
553	Huntington Disease: Genetics, Prevention, and Therapy Approaches. 2017 , 987, 55-65	4

552	Biomarkers of Disorders of the Nervous System. 2017 , 463-610	1
551	Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites. 2017 , 17, 281-285	3
550	Therapies targeting DNA and RNA in Huntington's disease. 2017 , 16, 837-847	175
549	Reply to 'Addiction as a brain disease does not promote injustice'. 2017 , 1, 611	6
548	NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington's Disease Suggests Altered Cell Energetics. 2017 , 16, 3863-3872	8
547	Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients. 2017 , 264, 2095-2100	5
546	From Disease to Health: Physical Therapy Health Promotion Practices for Secondary Prevention in Adult and Pediatric Neurologic Populations. 2017 , 41 Suppl 3, S46-S54	9
545	The CREST-E study of creatine for Huntington disease: A randomized controlled trial. 2017 , 89, 594-601	45
544	Huntington's Disease and Other Chorea. 2017 , 248-283	
543	Epidemiological Study of Huntington's Disease in the Province of Ferrara, Italy. 2017 , 49, 18-23	20
542	AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease. 2017 , 24, 630-639	48
541	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. 2017 , 6, 157-163	39
540	Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. 2017 , 6, 349-361	31
539	The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers. 2017 , 15, 129-161	7
538	Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models. 2017 , 7, 5070	22
537	Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats. 2017 , 16, 2692-2708	30
536	Presentation and care of a family with Huntington disease in a resource-limited community. 2017 , 4, 4	8
535	Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. 2017 , 4, 3	51

534	Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease. 2017 , 38, 5035-5050	19
533	Disclosing Huntington's Genetic Testing Results in the Context of Intellectual Disability and Guardianship: Using the Family Illness Narrative to Guide the Flow of Information. 2017 , 26, 272-275	1
532	The Ubiquitin Receptor ADRM1 Modulates HAP40-Induced Proteasome Activity. 2017 , 54, 7382-7400	9
531	Striatal synaptic dysfunction and altered calcium regulation in Huntington disease. 2017 , 483, 1051-1062	51
530	Possible role of mitochondrial permeability transition pore in the pathogenesis of Huntington disease. 2017 , 483, 1078-1083	25
529	Role of astrocyte-synapse interactions in CNS disorders. 2017 , 595, 1903-1916	88
528	TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease. 2017 , 360, 75-83	27
527	Mitochondrial cristae remodelling is associated with disrupted OPA1 oligomerisation in the Huntington's disease R6/2 fragment model. 2017 , 288, 167-175	17
526	Epidemiology of Huntington disease. 2017 , 144, 31-46	30
525	Resting-state functional MRI reveals altered brain connectivity and its correlation with motor dysfunction in a mouse model of Huntington's disease. 2017 , 7, 16742	11
524	Structural imaging in premanifest and manifest Huntington disease. 2017 , 144, 247-261	14
523	Statistical modeling of Huntington disease onset. 2017 , 144, 47-61	2
522	The diagnosis and natural history of Huntington disease. 2017 , 144, 63-67	8
521	Metal Biology Associated with Huntington's Disease. 2017 , 231-263	
520	. 2017 ,	1
519	Potential Therapeutic Effects of Lipoic Acid on Memory Deficits Related to Aging and Neurodegeneration. 2017 , 8, 849	39
518	CK2-An Emerging Target for Neurological and Psychiatric Disorders. 2017 , 10,	37
517	Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. 2017 , 18,	111

516	Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology. 2017 , 9, 166	43
515	Striatal Network Models of Huntington's Disease Dysfunction Phenotypes. 2017 , 11, 70	8
514	Molecular Imaging Markers to Track Huntington's Disease Pathology. 2017 , 8, 11	31
513	Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?. 2017 , 8, 91	9
512	Brain MRI Pattern Recognition Translated to Clinical Scenarios. 2017 , 11, 578	6
511	Differential Alteration in Expression of Striatal GABAR Subunits in Mouse Models of Huntington's Disease. 2017 , 10, 198	15
510	From open to large-scale randomized cell transplantation trials in Huntington's disease: Lessons from the multicentric intracerebral grafting in Huntington's disease trial (MIG-HD) and previous pilot studies. 2017 , 230, 227-261	21
509	Case Studies in Movement Disorders: Common and Uncommon Presentations. 81-82	
508	Protein Glutathionylation in the Pathogenesis of Neurodegenerative Diseases. 2017 , 2017, 2818565	21
507	Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease. 2017 , 12, e0168556	11
506	Distinct cellular toxicity of two mutant huntingtin mRNA variants due to translation regulation. 2017 , 12, e0177610	6
505	Medical management of motor manifestations of Huntington disease. 2017 , 144, 141-150	2
504	Motor outcome measures in Huntington disease clinical trials. 2017 , 144, 209-225	28
503	The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory. 2017 , 12, e0169051	12
502	Gene suppression approaches to neurodegeneration. 2017 , 9, 82	30
501	Human iPSC Models in Drug Discovery: Opportunities and Challenges. 2017 , 48-73	4
500	Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair. 2017 , 18,	41
499	From huntingtin gene to Huntington's disease-altering strategies. 2017 , 251-276	

498 Movement Disorders. **2017**, 149-166.e1

497	Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain. 2018 , 11, 79-90	21
496	Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease. 2018 , 34, 273-284	20
495	Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities. 2018 , 39, 754-769	30
494	Effect of Trinucleotide Repeats in the Huntington's Gene on Intelligence. 2018 , 31, 47-53	25
493	Nitric Oxide and Mitochondrial Function in Neurological Diseases. 2018 , 376, 48-71	48
492	Striatal neurons directly converted from Huntington's disease patient fibroblasts recapitulate age-associated disease phenotypes. 2018 , 21, 341-352	116
491	Novel Translational Research Methodology and the Prospect to a Better Understanding of Neurodegenerative Disease. 2018 , 18, 1-4	3
490	Clinical Features of Huntington's Disease. 2018 , 1049, 1-28	53
489	Genetic Modifiers in Neurodegeneration. 2018 , 6, 11-19	8
488	Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors. 2018 , 28, 307-322	18
487	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. 2018 , 39, 1339-1353	24
486	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. 2018 , 17, 312-324	14
485	Whole-Brain Connectivity in a Large Study of Huntington's Disease Gene Mutation Carriers and Healthy Controls. 2018 , 8, 166-178	26
484	Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntington's Disease. 2018 , 175, 400-407	7
483	An image-based model of brain volume biomarker changes in Huntington's disease. 2018 , 5, 570-582	31
482	Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease. 2018 , 30, 194-201	20
481	Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. 2018 , 26, 947-962	22

480	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. 2018 , 10,	305
479	Efficient ℓ_1 norm feature selection based on augmented and penalized minimization. 2018 , 37, 473-486	14
478	Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients. 2018 , 39, 54-71	5
477	Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures. 2018 , 27, 811-822	8
476	Therapy development in Huntington disease: From current strategies to emerging opportunities. 2018 , 176, 842-861	51
475	Understanding the need for assistance with survey completion in people with Huntington disease. 2018 , 27, 801-810	0
474	Molecular insights into cortico-striatal miscommunications in Huntington's disease. 2018 , 48, 79-89	20
473	Trinucleotide repeat disorders. 2017 , 145, 383-391	16
472	Progress in developing transgenic monkey model for Huntington's disease. 2018 , 125, 401-417	12
471	Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study. 2018 , 79, 13-20	16
470	Huntington's disease: a clinical review. 2018 , 25, 24-34	348
469	Thermoregulatory disorders in Huntington disease. 2018 , 157, 761-775	4
468	Gait, balance, and falls in Huntington disease. 2018 , 159, 251-260	15
467	Autophagy and Mitochondria: Targets in Neurodegenerative Disorders. 2018 , 17, 696-705	28
466	Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research. 2018 , 13, e0206478	17
465	The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database. 2018 , 9, 930	11
464	Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Chorea. 2018 , 18, 85	11
463	Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review. 2018 , 7, 345-353	3

462	Molecular Imaging in Huntington's Disease. 2018 , 142, 289-333	4
461	Novel Approach to Tracking Mutant Huntingtin in Biosamples. 2018 , 24, 978-981	
460	Vocalisation as a Viable Assessment for Phenotyping Minipigs Transgenic for the Huntington Gene?. 2018 , 7, 269-278	1
459	Learning Subject-Specific Directed Acyclic Graphs With Mixed Effects Structural Equation Models From Observational Data. 2018 , 9, 430	
458	Optogenetic Stimulation of GABAergic Neurons in the Globus Pallidus Produces Hyperkinesia. 2018 , 12, 185	10
457	Repeat-associated non-ATG (RAN) translation. 2018 , 293, 16127-16141	52
456	Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models. 2018 , 8,	56
455	Studying Huntington's Disease in Yeast: From Mechanisms to Pharmacological Approaches. 2018 , 11, 318	11
454	Therapeutic approaches to Huntington disease: from the bench to the clinic. 2018 , 17, 729-750	74
453	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. 2018 , 10,	67
452	Neuronal adenosine A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease. 2018 , 14, 235-243	8
451	Testing a longitudinal compensation model in premanifest Huntington's disease. 2018 , 141, 2156-2166	19
450	Genetic load determines atrophy in hand cortico-striatal pathways in presymptomatic Huntington's disease. 2018 , 39, 3871-3883	7
449	Astrocyte truncated tropomyosin receptor kinase B mediates brain-derived neurotrophic factor anti-apoptotic effect leading to neuroprotection. 2018 , 146, 686-702	29
448	Biofluid Biomarkers in Huntington's Disease. 2018 , 1780, 329-396	13
447	Translating Antisense Technology into a Treatment for Huntington's Disease. 2018 , 1780, 497-523	19
446	New directions in therapeutics for Huntington disease. 2018 , 13, 101-121	13
445	Baseline multimodal information predicts future motor impairment in premanifest Huntington's disease. 2018 , 19, 443-453	6

444	Catatonia in Children and Adolescents: A High Rate of Genetic Conditions. 2018 , 57, 518-525.e1	6
443	Perspectives on Genetic Testing and Return of Results from the First Cohort of Presymptomatically Tested Individuals At Risk of Huntington Disease. 2018 , 27, 1428-1437	3
442	An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. 2018 , 12, 464	118
441	Evidence of cardiac electrical remodeling in patients with Huntington disease. 2018 , 8, e01077	6
440	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. 2018 , 34, 545-568	57
439	Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease. 2018 , 9, 190	2
438	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. 2018 , 11, 2	67
437	Huntington's disease: Current and future therapeutic prospects. 2018 , 33, 1033-1041	28
436	Antiamyloidogenic Chemical/Biochemical-Based Designed Nanoparticle as Artificial Chaperone for Efficient Inhibition of Protein Aggregation. 2018 , 19, 1721-1731	22
435	The progression rate of spinocerebellar ataxia type 2 changes with stage of disease. 2018 , 13, 20	10
434	Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. 2018 , 11, 547-559	8
433	Macro roles for microRNAs in neurodegenerative diseases. 2018 , 3, 154-159	27
432	Gene therapy for neurological disorders: progress and prospects. 2018 , 17, 641-659	143
431	Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease. 2018 , 1780, 549-571	5
430	TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31. 2018 , 27, 2893-2912	19
429	A Transgenic Monkey Model of Huntington's Disease. 2018 , 593-615	
428	Huntington disease. 2018 , 147, 255-278	37
427	The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity. 2018 , 293, 11850-11866	9

426	Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?. 2018 , 27, 2541-2555	10
425	PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. 2019 , 691, 44-50	43
424	Behavioral Symptoms in Premanifest Huntington Disease Correlate with Reduced Frontal CBR Levels. 2019 , 60, 115-121	13
423	Polyglutamine Repeats in Neurodegenerative Diseases. 2019 , 14, 1-27	87
422	SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease. 2019 , 45, 361-379	19
421	Characterization of Neurodevelopmental Abnormalities in iPSC-Derived Striatal Cultures from Patients with Huntington's Disease. 2019 , 8, 257-269	9
420	Addressing the Value of Multidisciplinary Clinical Care in Huntington's Disease: A Snapshot of a New Huntington's Disease Center. 2019 , 8, 501-507	3
419	The Onset and Progression of Hippocampal Synaptic Plasticity Deficits in the Q175FDN Mouse Model of Huntington Disease. 2019 , 13, 326	8
418	Label Propagation Based Semi-supervised Feature Selection to Decode Clinical Phenotype of Huntington's Disease. 2019 , 529-542	
417	Speech in prodromal and symptomatic Huntington's disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases. 2019 , 107, 450-460	12
416	Pathomechanisms of Blood-Brain Barrier Disruption in ALS. 2019 , 2019, 2537698	24
415	White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease. 2019 , 24, 101965	18
414	Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington's Disease. 2019 , 19, 78-87	5
413	Exploring the Reliability and Validity of the Huntington's Disease Quality of Life Battery for Carers (HDQoL-C) within A Polish Population. 2019 , 16,	0
412	Detection of dentate nuclei abnormality in a patient with dentatorubral-pallidoluysian atrophy using the quantitative susceptibility mapping. 2019 , 403, 97-98	2
411	The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease. 2019 , 8, 375-391	20
410	Positive Attitudes and Therapeutic Misconception Around Hypothetical Clinical Trial Participation in the Huntington's Disease Community. 2019 , 8, 421-430	9
409	Predictive testing for Huntington disease over 24 years: Evolution of the profile of the participants and analysis of symptoms. 2019 , 7, e00881	3

408	Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice. 2020 , 38, 218-230	8
407	Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease. 2019 , 9, 16133	1
406	The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals. 2019 , 14, 246	3
405	Progressive Polyglutamine Repeat Expansion in Peripheral Blood Cells and Sperm of Transgenic Huntington's Disease Monkeys. 2019 , 8, 443-448	4
404	Nmnat restores neuronal integrity by neutralizing mutant Huntingtin aggregate-induced progressive toxicity. 2019 , 116, 19165-19175	14
403	Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. 2019 , 8, 467-482	7
402	Quercetin Encapsulated Polymer Nanoparticle for Inhibiting Intracellular Polyglutamine Aggregation.. 2019 , 2, 5298-5305	15
401	Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington's Disease. 2019 , 11, 34725-34735	50
400	CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model. 2019 , 17, 829-839	41
399	Regulatory roles of the miR-200 family in neurodegenerative diseases. 2019 , 119, 109409	6
398	Yeast Models for Amyloids and Prions: Environmental Modulation and Drug Discovery. 2019 , 24,	9
397	Activity Behaviour of Minipigs Transgenic for the Huntington Gene. 2019 , 8, 23-31	3
396	Manganese Enhanced MRI for Use in Studying Neurodegenerative Diseases. 2018 , 12, 114	12
395	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders. 2019 , 126, 997-1027	4
394	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. 2019 , 6, 541-546	30
393	Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. 2019 , 129, 118-129	25
392	A probabilistic disease progression modeling approach and its application to integrated Huntington's disease observational data. 2019 , 2, 123-130	13
391	'Real-life' hippocampal-dependent spatial memory impairments in Huntington's disease. 2019 , 119, 46-60	6

390	Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. 2019 , 8, 9	16
389	Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys. 2019 , 14, e0214156	10
388	Impaired Redox Signaling in Huntington's Disease: Therapeutic Implications. 2019 , 12, 68	27
387	PET/CT in Brain Disorders. 2019 ,	1
386	Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. 2019 , 101, 801-819	102
385	2,4 Dinitrophenol as Medicine. 2019 , 8,	45
384	Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems. 2019 , 294, 6986-7001	12
383	Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects. 2019 , 9, 4129	10
382	Engineering three-dimensional microenvironments towards in vitro disease models of the central nervous system. 2019 , 11, 032003	22
381	AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models. 2019 , 13, 334-343	28
380	[18F]FDG-PET/CT in Movement Disorders. 2019 , 49-64	
379	A Novel Ecological Approach Reveals Early Executive Function Impairments in Huntington's Disease. 2019 , 10, 585	4
378	Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice. 2019 , 4, 7	20
377	Identification of symbol digit modality test score extremes in Huntington's disease. 2019 , 180, 232-245	7
376	Attitudes of Potential Participants Towards Molecular Therapy Trials in Huntington's Disease. 2019 , 8, 79-85	5
375	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. 2019 , 63, 179-184	7
374	Huntingtin Aggregates and Mitochondrial Pathology in Skeletal Muscle but not Heart of Late-Stage R6/2 Mice. 2019 , 8, 145-159	9
373	The Challenges and Opportunities of Small Effects: The New Normal in Academic Psychiatry. 2019 , 76, 353-354	54

372	Exercise Interventions for the Management of Huntington's Disease. 2019 , 41, 62-68	
371	Research Domain Criteria: Strengths, Weaknesses, and Potential Alternatives for Future Psychiatric Research. 2019 , 5, 218-236	21
370	CD200 is up-regulated in R6/1 transgenic mouse model of Huntington's disease. 2019 , 14, e0224901	3
369	Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data. 2019 , 19, 318	14
368	Huntingtin's N-Terminus Rearrangements in the Presence of Membranes: A Joint Spectroscopic and Computational Perspective. 2019 , 10, 472-481	8
367	Melanocortin 4 receptor activation protects striatal neurons and glial cells from 3-nitropropionic acid toxicity. 2019 , 94, 41-51	8
366	Huntington Disease's Glial Progenitor Cells Hit the Pause Button in the Mouse Brain. 2019 , 24, 3-4	5
365	Hybrid PET-MRI Applications in Movement Disorders. 2019 , 144, 211-257	8
364	Effects of stimulus-related variables on mental states recognition in Huntington's disease. 2019 , 129, 563-572	2
363	Sample enrichment for clinical trials to show delay of onset in huntington disease. 2019 , 34, 274-280	6
362	Dynamic functional network connectivity in Huntington's disease and its associations with motor and cognitive measures. 2019 , 40, 1955-1968	27
361	The Expanding Clinical Universe of Polyglutamine Disease. 2019 , 25, 512-520	10
360	Leukocyte telomere shortening in Huntington's disease. 2019 , 396, 25-29	14
359	An active cognitive lifestyle as a potential neuroprotective factor in Huntington's disease. 2019 , 122, 116-124	11
358	Regional subcortical shape analysis in premanifest Huntington's disease. 2019 , 40, 1419-1433	16
357	Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease. 2019 , 121, 214-229	8
356	27 years of prenatal diagnosis for Huntington disease in the United Kingdom. 2019 , 21, 1639-1643	6
355	Designed Polymer Micelle for Clearing Amyloid Protein Aggregates via Up-Regulated Autophagy. 2019 , 5, 390-401	24

354	Treatment of psychiatric disturbances in common hyperkinetic movement disorders. 2019 , 19, 55-65	4
353	Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI. 2019 , 97, 467-479	23
352	Huntington disease: A quarter century of progress since the gene discovery. 2019 , 396, 52-68	36
351	Flexible Non-Negative Matrix Factorization to Unravel Disease-Related Genes. 2019 , 16, 1948-1957	4
350	Constructing disease onset signatures using multi-dimensional network-structured biomarkers. 2020 , 21, 122-138	
349	Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. 2020 , 29, 1757-1771	12
348	Gene therapy for neurological disorders: challenges and recent advancements. 2020 , 28, 111-128	10
347	Human pluripotent stem cell-derived models and drug screening in CNS precision medicine. 2020 , 1471, 18-56	31
346	Psychosis and longitudinal outcomes in Huntington disease: the COHORT Study. 2020 , 91, 15-20	9
345	Aberrant brain network connectivity in presymptomatic and manifest Huntington's disease: A systematic review. 2020 , 41, 256-269	18
344	Evaluation of a performance-rating method to assess awareness of cognitive functioning in Huntington's disease. 2020 , 34, 477-497	4
343	Longitudinal atrophy characterization of cortical and subcortical gray matter in Huntington's disease patients. 2020 , 51, 1827-1843	7
342	The effects of dual-task cognitive interference on gait and turning in Huntington's disease. 2020 , 15, e0226827	9
341	Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study. 2020 , 57, 2038-2047	5
340	Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. 2020 , 17, 252-268	28
339	One-year changes in brain microstructure differentiate preclinical Huntington's disease stages. 2020 , 25, 102099	5
338	Progressive cardiac arrhythmias and ECG abnormalities in the Huntington's disease BACHD mouse model. 2020 , 29, 369-381	26
337	Therapeutic strategies for ketosis induction and their potential efficacy for the treatment of acute brain injury and neurodegenerative diseases. 2020 , 133, 104614	11

336	An individual patient analysis of the efficacy of using GPI-DBS to treat Huntington's disease. 2020 , 13, 1722-1731	3
335	Structural brain correlates of dementia in Huntington's disease. 2020 , 28, 102415	6
334	Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases. 2020 , 14, 863	18
333	CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review. 2020 , 9, 419-434	11
332	Bioinformatic gene analysis for potential therapeutic targets of Huntington's disease in pre-symptomatic and symptomatic stage. 2020 , 18, 388	0
331	The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation. 2020 , 10,	8
330	Juvenile Huntington's disease: two case reports and a review of the literature. 2020 , 14, 173	
329	Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials. 2020 , 35, 2193-2200	6
328	AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins. 2020 , 20, 1121-1124	2
327	Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial. 2020 , 35, 1323-1335	10
326	Recognition of emotion from subtle and non-stereotypical dynamic facial expressions in Huntington's disease. 2020 , 126, 343-354	6
325	Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains. 2020 , 32, 108050	20
324	Cholesteryl ester levels are elevated in the caudate and putamen of Huntington's disease patients. 2020 , 10, 20314	5
323	Enhancing the Clinical Utility of DriveSafe DriveAware for People with Huntington's Disease. 2020 , 9, 353-357	
322	Personalized estimates of morphometric similarity in bipolar disorder and schizophrenia. 2020 , 6, 39	1
321	Molecular Mechanisms Underlying Muscle Wasting in Huntington's Disease. 2020 , 21,	8
320	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. 2020 , 57, 4667-4691	14
319	The P2X7 Receptor: Central Hub of Brain Diseases. 2020 , 13, 124	32

318	TENSOR-BASED GRADING: A NOVEL PATCH-BASED GRADING APPROACH FOR THE ANALYSIS OF DEFORMATION FIELDS IN HUNTINGTON'S DISEASE. 2020 , 2020, 1091-1095		1
317	Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2020 , 16, 529-546	15	80
316	Beyond Alzheimer's disease: Can bilingualism be a more generalized protective factor in neurodegeneration?. 2020 , 147, 107593		7
315	Applications of nanomaterials for scavenging reactive oxygen species in the treatment of central nervous system diseases. 2020 , 8, 8748-8767		14
314	Using Mendelian randomization to understand and develop treatments for neurodegenerative disease. 2020 , 2, fcaa031		4
313	DNA methylation study of Huntington's disease and motor progression in patients and in animal models. 2020 , 11, 4529		15
312	Fluorescent Diagnostic Probes in Neurodegenerative Diseases. 2020 , 32, e2001945		33
311	On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson's and Huntington's Disease. 2020 , 12, 571185		11
310	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. 2020 , 15, e0233820		3
309	Disease-related Huntingtin seeding activities in cerebrospinal fluids of Huntington's disease patients. 2020 , 10, 20295		3
308	Is Ataxia an Underestimated Symptom of Huntington's Disease?. 2020 , 11, 571843		5
307	Peripheral Levels of Renin-Angiotensin System Components Are Associated With Cognitive Performance in Huntington's Disease. 2020 , 14, 594945		0
306	Determining the Fate of Neurons in SCA3: ATX3, a Rising Decision Maker in Response to DNA Stresses and Beyond. 2020 , 8, 619911		0
305	Sleep Dysfunction in Huntington's Disease: Perspectives from Patients. 2020 , 9, 345-352		1
304	Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales. 2020 , 60, 1051-1060		5
303	Cognitive and Motor Norms for Huntington's Disease. 2020 , 35, 671-682		3
302	Deficits in coordinated neuronal activity and network topology are striatal hallmarks in Huntington's disease. 2020 , 18, 58		3
301	Discovery of Small Molecule Inhibitors of Huntingtin Exon 1 Aggregation by FRET-Based High-Throughput Screening in Living Cells. 2020 , 11, 2286-2295		7

300	Imbalance of the oxytocin-vasopressin system contributes to the neuropsychiatric phenotype in the BACHD mouse model of Huntington disease. 2020 , 119, 104773	4
299	Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. 2020 , 30, 2003054	38
298	Fifteen Years of Wireless Sensors for Balance Assessment in Neurological Disorders. 2020 , 20,	31
297	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. 2020 , 18, 140	16
296	Morphometric in vivo evidence of thalamic atrophy correlated with cognitive and motor dysfunction in Huntington's disease: The IMAGE-HD study. 2020 , 298, 111048	1
295	Psychological reactions to predictive genetic testing for Huntington's disease: A qualitative study. 2020 , 29, 1093-1105	5
294	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local Amyloid, Tau, and APOE4. 2020 , 12, 46	8
293	Psychiatric morbidity and poor follow-up underlie suboptimal functional and survival outcomes in Huntington's disease. 2020 , 20, 87	2
292	Striatal connectivity in pre-manifest Huntington's disease is differentially affected by disease burden. 2020 , 27, 2147-2157	4
291	Clinical, radiological, and genetic characteristics in patients with Huntington's disease in a Taiwanese cohort. 2020 , 183, 352-359	0
290	Structural and functional features of medium spiny neurons in the BACHD Δ 17 mouse model of Huntington's Disease. 2020 , 15, e0234394	2
289	Family Communication Patterns and Challenges of Huntington's Disease Risk, the Decision to Pursue Presymptomatic Testing, and Test Results. 2020 , 9, 265-274	4
288	Nanoengineered biomaterials for neurodegenerative disorders. 2020 , 713-734	1
287	Cognition, function and awareness of disease impact in early Parkinson's and Huntington's disease. 2020 , 1-19	2
286	Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease. 2020 , 267, 1527-1535	8
285	Autoscopic phenomena as an atypical psychiatric presentation of Huntington's disease: A case report including longitudinal clinical and neuroimaging data. 2020 , 125, 299-306	
284	Cortical and Striatal Circuits in Huntington's Disease. 2020 , 14, 82	20
283	Trehalose-Conjugated, Catechin-Loaded Polylactide Nanoparticles for Improved Neuroprotection against Intracellular Polyglutamine Aggregates. 2020 , 21, 1578-1586	14

282	Pridopidine in the treatment of Huntington's disease. 2020 , 31, 441-451	3
281	A Generative Adversarial Network Model for Disease Gene Prediction With RNA-seq Data. 2020 , 8, 37352-37360	2
280	Assessing Mental Health Difficulties of Persons With Huntington's Disease: Does Informant Presence Make a Difference?. 2020 , 32, 244-251	3
279	Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients. 2019 , 12, 335	15
278	Accuracy of automated amygdala MRI segmentation approaches in Huntington's disease in the IMAGE-HD cohort. 2020 , 41, 1875-1888	3
277	Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA. 2020 , 34, 219-228	17
276	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. 2020 , 35, 606-615	14
275	Therapeutic Advances for Huntington's Disease. 2020 , 10,	27
274	Glutamine Synthetase 1 Increases Autophagy Lysosomal Degradation of Mutant Huntingtin Aggregates in Neurons, Ameliorating Motility in a Model for Huntington's Disease. 2020 , 9,	4
273	Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein. 2020 , 11, 1334-1348	4
272	Mutant Huntingtin affects toll-like receptor 4 intracellular trafficking and cytokine production in mast cells. 2020 , 17, 95	10
271	Rutin protects Huntington's disease through the insulin/IGF1 (IIS) signaling pathway and autophagy activity: Study in <i>Caenorhabditis elegans</i> model. 2020 , 141, 111323	22
270	The cholesterol 24-hydroxylase activates autophagy and decreases mutant huntingtin build-up in a neuroblastoma culture model of Huntington's disease. 2020 , 13, 210	5
269	Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks. 2020 , 77, 764-772	16
268	Medical, Surgical, and Genetic Treatment of Huntington Disease. 2020 , 38, 367-378	6
267	A novel specific PERK activator reduces toxicity and extends survival in Huntington's disease models. 2020 , 10, 6875	17
266	Injured adult neurons regress to an embryonic transcriptional growth state. 2020 , 581, 77-82	65
265	Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology. 2020 , 17, 98	28

264	Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders. 2020 , 8, 238	43
263	Computational approaches and machine learning for individual-level treatment predictions. 2021 , 238, 1231-1239	6
262	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. 2021 , 92, 143-149	3
261	Advances in the computational understanding of mental illness. 2021 , 46, 3-19	17
260	The Role of the Cerebellum in Huntington's Disease: a Systematic Review. 2021 , 20, 254-265	2
259	Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease. 2021 , 36, 481-491	3
258	Cortical morphometry and neural dysfunction in Huntington's disease: a review. 2021 , 28, 1406-1419	4
257	Neuropsychiatric comorbidities in Huntington's and Parkinson's Disease: A United States claims database analysis. 2021 , 8, 126-137	2
256	Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective. 2021 , 28, 439-454	11
255	Impaired response of cerebral oxygen metabolism to visual stimulation in Huntington's disease. 2021 , 41, 1119-1130	2
254	Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks. 2021 , 30, 251-265	1
253	Implications of Adult Neural Stem Cell Abnormalities in the Pathophysiological Mechanism of Schizophrenia. 2021 , 60, 28	
252	Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology. 2021 , 11,	7
251	Altered microRNA expression in animal models of Huntington's disease and potential therapeutic strategies. 2021 , 16, 2159-2169	3
250	Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. 2021 , 183, 175-196	1
249	Enhanced GABAergic Inhibition of Cholinergic Interneurons in the zQ175 Mouse Model of Huntington's Disease. 2020 , 14, 626412	2
248	Protective Effect of Natural Products against Huntington's Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action. 2021 , 12, 391-418	8
247	Management of Motor Symptoms in Dementia Disorders. 2021 , 201-227	

246	Huntington disease. 2021 , 371-400.e14	
245	Contribution of gut microbiota in the pathogenesis of amyotrophic lateral sclerosis and Huntington's disease. 2021 , 87-100	1
244	Huntington's disease among immigrant groups and Swedish-born individuals: a cohort study of all adults 18 years of age and older in Sweden. 2021 , 42, 3851-3856	0
243	Huntington's Disease. 2021 , 461-494	
242	Linking Huntington disease, brain-derived neurotrophic factor, and depressive-like behaviors. 2021 , 161-177	0
241	Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies. 2021 , 121, 201-219	11
240	CNS critical periods: implications for dystonia and other neurodevelopmental disorders. 2021 , 6,	4
239	Timing of selective basal ganglia white matter loss in Huntington's disease.	1
238	Cerebrospinal Fluid Markers of Medium Spiny Neuron Injury in Huntington's Disease. 2021 , 36, 280-282	
237	CAG repeat instability in embryonic stem cells and derivative spermatogenic cells of transgenic Huntington's disease monkey. 2021 , 38, 1215-1229	2
236	What is the Pathogenic CAG Expansion Length in Huntington's Disease?. 2021 , 10, 175-202	7
235	Neurocognitive Features of Motor Premanifest Individuals With Myotonic Dystrophy Type 1. 2021 , 7, e577	2
234	Dysfunction of the SNARE complex in neurological and psychiatric disorders. 2021 , 165, 105469	7
233	Selective Activation of CNS and Reference Promoters Is Associated with Distinct Gene Programs Relevant for Neurodegenerative Diseases. 2021 , 22,	2
232	Sex Differences in Huntington's Disease: Evaluating the Enroll-HD Database. 2021 , 8, 420-426	4
231	Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy. 2021 , 13,	12
230	Genomic architecture differences at the HTT locus associated with symptomatic and pre-symptomatic cases of Huntington's disease in a pilot study. 2021 , 1-6	0
229	Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology. 2021 , 8,	6

228	Revisiting cell and gene therapies in Huntington's disease. 2021 , 99, 1744-1762	3
227	Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study. 2021 , 12, 657973	2
226	The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases. 2021 , 1-38	1
225	Expression of Reprogramming Factor OCT4 Ameliorates Myelination Deficits and Induces Striatal Neuroprotection in Huntington's Disease. 2021 , 12,	1
224	Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform. 2021 , 18,	0
223	Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. 2021 , 152, 105293	3
222	Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers. 2021 , 36, 2282-2292	0
221	Ranking the Predictive Power of Clinical and Biological Features Associated With Disease Progression in Huntington's Disease. 2021 , 12, 678484	0
220	Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease. 2021 , 36, 2162-2172	2
219	Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study. 2021 , 144, 3101-3113	3
218	RNA toxicity and perturbation of rRNA processing in spinocerebellar ataxia type 2.	
217	Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction. 2021 , 16, e0252683	2
216	The Relationship Between Plasma Oxytocin and Executive Functioning in Huntington's Disease: A Pilot Study. 2021 , 10, 349-354	2
215	GEORGE : A Pilot Study of a Smartphone Application for Huntington's Disease. 2021 , 10, 293-301	1
214	Structural insight into transmissive mutant huntingtin species by correlative light and electron microscopy and cryo-electron tomography. 2021 , 560, 99-104	1
213	Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease.. 2022 , 9, 479-493	0
212	Past, present and future role of retinal imaging in neurodegenerative disease. 2021 , 83, 100938	16
211	Huntington's Chorea-a Rare Neurodegenerative Autosomal Dominant Disease: Insight into Molecular Genetics, Prognosis and Diagnosis. 2021 , 193, 2634-2648	1

210	In Situ Monitored Vortex Fluidic-Mediated Protein Refolding/Unfolding Using an Aggregation-Induced Emission Bioprobe. 2021 , 26,	0
209	Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease. 2021 , 154, 105336	5
208	Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics. 2021 , 30, 2469-2487	0
207	Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington's Disease: A Pilot Study. 2020 , 20, 207-211	0
206	Accelerated expansion of pathogenic mitochondrial DNA heteroplasmies in Huntington's disease. 2021 , 118,	1
205	Exosomes as a potential messenger unit during heterochronic parabiosis for amelioration of Huntington's disease. 2021 , 155, 105374	5
204	Label propagation-based semi-supervised feature selection on decoding clinical phenotypes with RNA-seq data. 2021 , 14, 141	0
203	MicroRNAs in Huntington's Disease: Diagnostic Biomarkers or Therapeutic Agents?. 2021 , 15, 705348	3
202	Integrative enrichment analysis of gene expression based on an artificial neuron. 2021 , 14, 173	0
201	RNA Toxicity and Perturbation of rRNA Processing in Spinocerebellar Ataxia Type 2. 2021 , 36, 2519-2529	2
200	Cognition-oriented treatments and physical exercise on cognitive function in Huntington's disease: Protocol for systematic review.	0
199	Endophenotypical drift in Huntington's disease: a 5-year follow-up study. 2021 , 16, 340	2
198	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. 2021 , 6, 910-918	1
197	Huntington's Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System For Staging.	1
196	circRNA Regulates Dopaminergic Synapse, MAPK, and Long-term Depression Pathways in Huntington Disease. 2021 , 58, 6222-6231	0
195	Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington's disease.	0
194	Cognition-oriented treatments and physical exercise on cognitive function in Huntington's disease: protocol for systematic review. 1-6	0
193	Fixel-Based Analysis Effectively Identifies White Matter Tract Degeneration in Huntington's Disease. 2021 , 15, 711651	1

192	The emerging role of miRNA-132/212 cluster in neurologic and cardiovascular diseases: Neuroprotective role in cells with prolonged longevity. 2021 , 199, 111566	0
191	Rapid quantification of extracellular neurotransmitters in mouse brain by PESI/MS/MS and longitudinal data analysis using the R and Stan-based Bayesian state-space model. 2021 , 234, 122620	3
190	Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.. 2021 , 144, 3421-3435	2
189	Huntington Disease. 2021 , 161-180	
188	Basal Ganglia Anatomy, Biochemistry, and Physiology. 2016 , 3-12	1
187	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease.	2
186	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.	0
185	HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity.	2
184	Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties.	5
183	Dynamics of cortical degeneration over a decade in Huntington's Disease.	3
182	Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease. 2017 , 2,	27
181	Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington's disease.. 7, 1757	1
180	Genomic architecture differences at the HTT locus associated with symptomatic and pre-symptomatic cases of Huntington's disease in a pilot study.. 7, 1757	1
179	N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy. 2016 , 12, e1006083	9
178	Systems Genetic Analyses Highlight a TGF- β /FOXO3 Dependent Striatal Astrocyte Network Conserved across Species and Associated with Stress, Sleep, and Huntington's Disease. 2016 , 12, e1006137	18
177	Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease. 2014 , 9, e107691	15
176	Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease. 2015 , 10, e0145333	16
175	Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?. 2017 , 12, e0172762	30

174	Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease. 2017 , 12, e0175968	8
173	Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays. 2017 , 12, e0189891	9
172	MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice. 2018 , 13, e0190550	19
171	Cortico-Striatal Cross-Frequency Coupling and Gamma Genesis Disruptions in Huntington's Disease Mouse and Computational Models. 2018 , 5,	8
170	Hippocampal Synaptic Dysfunction in a Mouse Model of Huntington Disease Is Not Alleviated by Ceftriaxone Treatment. 2020 , 7,	7
169	Reviewing Biochemical Implications of Normal and Mutated Huntingtin in Huntington's Disease. 2020 , 27, 5137-5158	3
168	Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective. 2020 , 20, 184-194	17
167	Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington's Disease-associated Chorea Initiated on Tetrabenazine. 2018 , 6, 15-24	2
166	Clinical trial perspective for adult and juvenile Huntington's disease using genetically-engineered mesenchymal stem cells. 2016 , 11, 702-5	23
165	Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ tract. 2016 , 5,	41
164	Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease. 2018 , 7,	37
163	Huntington Disease: The Complexities of Making and Disclosing a Clinical Diagnosis After Premanifest Genetic Testing. 2017 , 7, 467	3
162	Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntington's Disease. 2021 , 10, 459-468	1
161	Imaging Biomarkers in Huntington's Disease. 2022 , 457-505	
160	Non-monotonic fibril surface occlusion by GFP tags from coarse-grained molecular simulations.	
159	Longitudinal Evaluation of Magnetic Resonance Spectroscopy Metabolites as Biomarkers in Huntington's Disease.	0
158	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. 2021 ,	4
157	Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease. 2021 , 49, 1166	1

- 156 A long way to go: caspase inhibitors in clinical use. **2021**, 12, 949 3
- 155 Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. **2021**, 22, 9
- 154 The Structure and Functions of PRMT5 in Human Diseases. **2021**, 11, 3
- 153 Cognitive Impairment and Dementia (Mild or Major Neurocognitive Disorder) in Huntington's Disease. **2015**, 211-222
- 152 Pin1 and neurodegeneration: a new player for prion disorders?. **2015**, 2, 311-323
- 151 Peripheral Htt silencing does not ameliorate central signs of disease in the B6. HttQ111/+ mouse model of Huntington's Disease.
- 150 Major Neurocognitive Disorder of Rapid Progression in Huntington's Disease Associated with Triplet Repeat CAG. **2017**, 2,
- 149 Can Machine Learning fMRI Be A Computer Aided Diagnosis Tool For Brain Diseases?. **2018**,
- 148 Care of Patients with Neurologic Disease. **2018**, 375-386
- 147 Design and characterisation of mutant and wild-type huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems. 1
- 146 Neurodegenerative Diseases: Huntington Disease. **2019**, 1059-1068
- 145 Integrative Enrichment Analysis of Intra- and Inter- Tissues Differentially Expressed Genes Based on Perceptron. **2019**, 93-104
- 144 Metabolic Alterations Amalgamated with Huntington's Disease. **2019**, 163-183
- 143 Retinal and choroidal morphological changes in Huntington's disease. **2019**, 12, 56-63
- 142 Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington's disease.. 7, 1757
- 141 Glutamine Synthetase-1 induces autophagy-lysosomal degradation of huntingtin aggregates and ameliorates animal motility in a Drosophila model for Huntington's disease. 1
- 140 The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases. **2019**, 23, 335-360 5
- 139 Psychiatric morbidity and poor follow-up underlie suboptimal functional and survival outcomes in Huntington's disease.

138	Metabolomics in degenerative brain diseases. 2021 , 1773, 147704	2
137	Time-varying Hazards Model for Incorporating Irregularly Measured, High-Dimensional Biomarkers. 2020 , 30, 1605-1632	
136	Risk-Taking Behaviors in Huntington's Disease. 2020 , 9, 359-369	3
135	Huntington's disease in Turkey: genetic counseling, clinical features, and outcome. 2021 , 43, 381-386	
134	Variants in an Iberian Alzheimer Cohort Detected through an Optimized Sanger Sequencing Protocol. 2020 , 12,	0
133	Patch-Based Abnormality Maps for Improved Deep Learning-Based Classification of Huntington's Disease. 2020 , 12267, 636-645	1
132	Diagnostische Verfahren. 2020 , 551-631	
131	Role of cellular oxidative stress in dementia. 2020 , 147-161	
130	K-means Based Unsupervised Feature Selection to Prioritize Biomarkers of Different Disease Clinical Phases.	0
129	Structure and Dynamics of Large-Scale Cognitive Networks in Huntington's Disease. 2021 ,	0
128	Single-cell Transcriptional Changes in Neurodegenerative Diseases. 2021 , 479, 192-205	2
127	HTTsilencing delays onset and slows progression of Huntington's disease like phenotype: Monitoring with a novel neurovascular biomarker.	1
126	Prevalence of Trinucleotide Expansions in SCA17/TBP and JPH3 Genes and Octapeptide Insertion in PRNP Gene in Iranian Patients with Huntington-Disease like Syndrome. 2020 , 14, 19-24	
125	An Exploration of Latent Structure in Observational Huntington's Disease Studies. 2017 , 2017, 92-102	2
124	A Data-Driven Method for Generating Robust Symptom Onset Indicators in Huntington's Disease Registry Data. 2017 , 2017, 1635-1644	2
123	G-Computation and Hierarchical Models for Estimating Multiple Causal Effects From Observational Disease Registries With Irregular Visits. 2019 , 2019, 789-798	1
122	Huntington's disease with comorbid myasthenia gravis: a case report. 2019 , 23, 28-29	
121	Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review. 2021 , 12, 712555	3

120	Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties. 2021 , 12, 6579	4
119	Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington's disease. 2021 , 12, 585	0
118	Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity. 2021 , 49, 12069-12088	1
117	Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease. 2021 , 12, 779890	0
116	The oral manifestations of Huntington's disease: A systematic review of prevalence. 2021 ,	0
115	Non-monotonic fibril surface occlusion by GFP tags from coarse-grained molecular simulations.. 2022 , 20, 309-321	0
114	Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review. 2021 , 12, 712555	3
113	Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study. 2021 ,	3
112	Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders.. 2022 , 10,	0
111	RNA-Targeting CRISPR/Cas13d System Eliminates Disease-Related Phenotypes in Pre-clinical Models of Huntington's Disease.	0
110	Longitudinal mapping of cortical surface changes in Huntington's Disease.. 2022 , 1	0
109	Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.. 2022 ,	2
108	A Machine-Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design. 2021 ,	5
107	Preventive drugs for Huntington's disease: A choice-based conjoint survey of patient preferences.. 2022 , 6, e35	
106	Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders.. 2022 , 12,	1
105	Defining Utility Values for Chorea Health States in Patients with Huntington's Disease.. 2022 , 39, 1784	
104	Disease Burden of Huntington's Disease (HD) on People Living with HD and Care Partners in Canada.. 2022 ,	1
103	Siah-1-interacting protein regulates mutated huntingtin protein aggregation in Huntington's disease models.. 2022 , 12, 34	

102	Multifunctional Therapeutic Approach of Nanomedicines against Inflammation in Cancer and Aging. 2022 , 2022, 1-19	10
101	Class A and C GPCR dimers in neurodegenerative diseases.. 2022 ,	
100	The first patient with sporadic Huntington's disease due to a de novo (CAG) _n expansion in China. 2022 ,	
99	Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: Cross talk between PPAR- α and PI3K/Akt/GSK-3 β pathway.. 2022 , 120480	1
98	GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain. 2021 , 12, 6666	6
97	Drug Treatment of Psychiatric Symptoms Occurring in the Context of Other Disorders. 777-830	0
96	Targeted Genetic Reduction of Mutant Huntingtin Lessens Cardiac Pathology in the BACHD Mouse Model of Huntington's Disease.. 2021 , 8, 810810	0
95	Microglia Mediate Early Corticostriatal Synapse Loss and Cognitive Dysfunction in Huntington's Disease Through Complement-Dependent Mechanisms.	1
94	Variation in subcortical anatomy: relating interspecies differences, heritability, and brain-behavior relationships.	
93	Standardizing the CAP Score in Huntington's Disease by Predicting Age-at-Onset.. 2022 ,	2
92	Counseling and prenatal diagnosis in facioscapulohumeral muscular dystrophy: A retrospective study on a 13-year multidisciplinary approach.. 2022 , 5, e614	0
91	Data_Sheet_1.PDF. 2018 ,	
90	data_sheet_1.docx. 2018 ,	
89	table_1.xlsx. 2018 ,	
88	Image_1.tiff. 2020 ,	
87	Image_2.tiff. 2020 ,	
86	Image_3.tiff. 2020 ,	
85	Image_4.tiff. 2020 ,	

84 Image_5.tiff. **2020**,

83 Image_6.tiff. **2020**,

82 Table_1.DOCX. **2020**,

81 Image_1.TIF. **2018**,

80 Table_1.DOCX. **2018**,

79 Data_Sheet_1.PDF. **2020**,

78 Data_Sheet_2.PDF. **2020**,

77 Data_Sheet_3.pdf. **2020**,

76 Video_1.MOV. **2018**,

75 Classification of Huntington's Disease Stage with Features Derived from Structural and Diffusion-Weighted Imaging. **2022**, 12, 704

74 MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.. **2022**, 23,

2

73 Clinical Correlates of Depression and Suicidality in Huntington Disease: An Analysis of the Enroll-HD Observational Study.. **2022**,

72 Natural History and Burden of Huntington's Disease in the UK: A Population-Based Cohort Study.. **2022**,

0

71 Effects of Exercise on Skeletal Muscle Pathophysiology in Huntington's Disease. **2022**, 7, 40

70 What did we learn from neural grafts in Huntington disease?. **2022**,

69 Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population. 1-13

68 Differential tractography as a dynamic imaging biomarker: A methodological pilot study for Huntington's disease. **2022**, 35, 103062

67 Diapocynin neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: emphasis on Sirt1/Nrf2 signaling pathway.

0

- 66 A biological classification of Huntington's disease: the Integrated Staging System. **2022**, 21, 632-644 5
- 65 Basal Ganglia Anatomy, Biochemistry, and Physiology. **2022**, 3-13
- 64 Changes in brain activity with tominersen in early-manifest Huntington's disease. **2022**, 4, 0
- 63 The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders. **2022**, 11, 1
- 62 The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.
- 61 The Repeatable Battery for the Assessment of Neuropsychological Status, While Useful for Measuring Cognitive Changes in Manifest Huntington Disease, May Show Limited Utility in Premanifest Disease. Publish Ahead of Print,
- 60 Huntington disease. **2023**, 275-292
- 59 An MDS Evidence-Based Review on Treatments for Huntington's Disease. **2022**, 37, 1566-1567
- 58 Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies.
- 57 HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis. **2022**, 18, e1010302 0
- 56 Social cognition and quality of life in Huntington's disease. 13,
- 55 Cerebral blood flow is associated with markers of neurodegeneration in Huntington's disease. **2022**, 102, 79-85
- 54 Oxytocin in Huntington's disease and the spectrum of amyotrophic lateral sclerosis-frontotemporal dementia. 15, 2
- 53 Apathy and Depression in Huntington's Disease: Distinct Longitudinal Trajectories and Clinical Correlates. 1
- 52 Inflammasome activation and assembly in Huntington's disease. **2022**, 151, 134-142 0
- 51 MicroRNAs in neurological diseases. **2022**, 317-329 0
- 50 Huntington's Disease: A Clinical Review. **2022**, 0
- 49 Neuropathology of Huntington's Disease. 0

- 48 Focusing the pivotal role of nanotechnology in Huntington's disease: an insight into the recent advancements. 1
- 47 Medial prefrontal transcranial alternating current stimulation for apathy in Huntington's disease. 0
- 46 Challenges of translating a cell therapy to GMP. **2022**, 0
- 45 Discovery of an autophagy inducer J3 to lower mutant huntingtin and alleviate Huntington's disease-related phenotype. **2022**, 12, 0
- 44 Automated and objective analysis of speech in premanifest and early-stage Huntington's disease. 0
- 43 Delineating apathy profiles in Huntington's disease with the short-Lille Apathy Rating Scale. **2022**, 0
- 42 Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease. 0
- 41 Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019). 0
- 40 Age-related Huntington's disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy. **2022**, 25, 1420-1433 1
- 39 Dietary ketosis improves circadian dysfunction as well as motor symptoms in the BACHD mouse model of Huntington's disease. 9, 0
- 38 Magnetic resonance imaging in Huntington's disease. **2023**, 449-489 0
- 37 An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons. **2022**, 13, 0
- 36 Motivationally salient cue processing measured using the monetary incentive delay (mid) task with electroencephalography (EEG): A potential marker of apathy in Huntington's disease. **2022**, 108426 0
- 35 Emerging polymeric biomaterials and manufacturing-based tissue engineering approaches for neuro regeneration-A critical review on recent effective approaches. **2023**, 4, 337-355 1
- 34 Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules. **2022**, 11, 1
- 33 Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity. **2022**, 4, 0
- 32 Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential. **2022**, 10, 3000 0
- 31 Ex vivo 100 μ m isotropic diffusion MRI-based tractography of connectivity changes in the end-stage R6/2 mouse model of Huntington's disease. 0

- 30 Widespread dysregulation of mRNA splicing implicates RNA processing in the development and progression of Huntington's disease. ○
- 29 An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models. ○
- 28 Cognition-oriented treatments and physical exercise on cognitive function in Huntington's disease: a systematic review. ○
- 27 Detection of antibodies against the huntingtin protein in human plasma. **2023**, 80, ○
- 26 Understanding the Relationship Between Perseveration, Comorbid Behavioral Symptoms, Motor Decline, Functional Decline, and Self-report Accuracy in Huntington Disease Can Help Inform Clinical Practice. Publish Ahead of Print, ○
- 25 Death Anxiety in Huntington Disease: Longitudinal Health-Related Quality-of-Life Outcomes. ○
- 24 Health care resource utilization and costs among individuals with vs without Huntington disease in a US population. **2022**, 28, 1228-1239 ○
- 23 Factors Associated with the Place of Death in Huntington Disease: Analysis of Enroll-HD. ○
- 22 Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach. 13, ○
- 21 The updated development of blood-based biomarkers for Huntington's disease. ○
- 20 Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease. **2023**, 24, 6051 ○
- 19 Non-Invasive Neuromodulation Methods to Alleviate Symptoms of Huntington's Disease: A Systematic Review of the Literature. **2023**, 12, 2002 ○
- 18 Divergent cognitive trajectories in early stage Huntington's disease: A 3-year longitudinal study. ○
- 17 The pyruvate dehydrogenase complex: Life's essential, vulnerable and druggable energy homeostat. **2023**, 70, 59-102 ○
- 16 A comprehensive perspective of Huntington's disease and mitochondrial dysfunction. **2023**, 70, 8-19 ○
- 15 Neural circuit changes in neurological disorders: Evidence from in vivo two-photon imaging. **2023**, 87, 101933 ○
- 14 Application of Novel Degradable Employing Autophagy for Expediting Medicinal Research. **2023**, 66, 1700-1711 ○
- 13 Disentangling the neurobiological bases of temporal impulsivity in Huntington's disease. ○

- 12 Hydrogen Sulphide-Based Therapeutics for Neurological Conditions: Perspectives and Challenges. ○
- 11 Effects of mutant huntingtin in oxytocin neurons on non-motor features of Huntington's disease. **2023**, 49, ○
- 10 Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model. ○
- 9 Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington's Disease-Associated Chorea Initiated on Tetrabenazine. 15-24 ○
- 8 Sphingolipids and impaired hypoxic stress responses in Huntington disease. **2023**, 90, 101224 ○
- 7 Progressive alterations in white matter microstructure across the timecourse of Huntington's disease. **2023**, 13, ○
- 6 Advance Care Planning and Health-Related Quality of Life in Huntington Disease: Results from a Multicenter National Study. **2023**, 4, 79-88 ○
- 5 Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies. **2023**, 13, ○
- 4 Contribution of Glial Cells to Polyglutamine Diseases: Observations from Patients and Mouse Models. **2023**, 20, 48-66 ○
- 3 Otros trastornos del movimiento, tics, corea. **2023**, 13, 4505-4515 ○
- 2 A patent review of PRMT5 inhibitors to treat cancer (2018 to present). ○
- 1 Defining Clinical Meaningfulness in Huntington's Disease. ○